There has been little respite lately for India’s stumbling economy, lashed by close to double-digit inflation and a rupee that fell by 16% in the past year. That wiped out any gain from the 12% rise of the stock market, resulting in a lackluster 3% growth in the wealth of India’s 100 richest, to $259 billion.
There has been little respite lately for India’s stumbling economy, lashed by close to double-digit inflation and a rupee that fell by 16% in the past year. That wiped out any gain from the 12% rise of the stock market, resulting in a lackluster 3% growth in the wealth of India’s 100 richest, to $259 billion.
But amid the gloom are a few rays of sunshine, notably in export-led sectors such as IT and pharma that have benefited from the weaker rupee and hopes of a continuing U.S. revival. Shining brightest among that lot is the founder of India’s most valuable drugmaker, Sun Pharmaceutical Industries , Dilip Shanghvi. He is the year’s biggest dollar gainer and moves to No. 3 for the first time. His $4.7 billion gain accounts for half of overall increase. He takes the spot of tech tycoon Azim Premji, who didn’t do badly, but his $1.6 billion gain was no match for Shanghvi’s.
Disclaimer: Ventura Securities Ltd has taken due care and caution in compilation of data for its web blog. The information has been obtained from different sources which it considers reliable. However, Ventura Securities Ltd does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Ventura Securities Ltd especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its web blog. The information provided herein is just for the knowledge purpose and shouldn’t be construed as investment advice under any circumstances.
Post your comment
You must be logged in to post a comment.